Under the agreement, Mubadala will establish the facility that will be operated by the California-based US company and manufacture a range of therapeutics for complex diseases such as cancer, infectious diseases, and inflammatory and autoimmune disorders, as well as vaccines.

Mubadala said it has invested in multiple rounds of equity financing in Resilience over the past two years and the partnership is in line with the UAE’s industrial strategy, which has identified life sciences as a priority sector.

Resilience CEO Rahul Singhvi said the deal marked a significant milestone. He commented: “We are excited to expand the footprint of our Resilience manufacturing network outside of North America. We look forward to working alongside America’s allies in the region to ensure that trusted, cutting-edge biopharmaceutical manufacturing capacity is available to support local, regional, and global economies.”

Last November, Resilience announced that it was to establish a long-term biomanufacturing partnership with AstraZeneca, under which it was to acquire the latter’s facility in West Chester, Ohio and manufacture certain of the drugmaker’s products as part of a multi-year supply agreement.

Author: Elaine Burridge, Freelance Journalist